| Date | Title | Description |
| 12.01.2022 | Transcarent Raises $200 Million in Series C Funding Highlighting Growing Demand for a Different Health and Care Experience Aligned with the Needs of Self-Insured Employers | Led by Kinnevik and Human Capital and joined by Ally Bridge Group, General Catalyst, 7wireVentures and existing Transcarent investors
Leading health systems Northwell Health, Intermountain Healthcare, and Rush University Medical Center inv... |
| 09.11.2021 | Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precision Editing Therapeutics | The most extensive toolbox of proprietary genomic editors in the industry to enable development of curative, next-generation genetic medicines
Co-founded by David Walt, Ph.D. and Feng Zhang, Ph.D.
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NE... |
| 02.11.2021 | Shoreline Biosciences Announces $140M Financing To Advance Pipeline Of Next Generation Cell Immunotherapies | Financing accelerates the growth of Shoreline’s pipeline of iPSC-based cell immunotherapies for the treatment of seriously ill patients and enables the buildout of smart manufacturing capabilities
SAN DIEGO, Nov. 2, 2021 /PRNewswire/ — Sho... |
| 26.10.2021 | Quantum Surgical Secures 40 Million Euros to Support the Commercial Launch of Epione Its unique Medical Robot | Montpellier, France, October 19th, 2021 – Quantum Surgical, an innovative medical robotic company, announced today that it has secured €40 million (US$48 million) of financing. Led by existing key investor Ally Bridge Group (“ABG”) with an ... |
| 08.10.2021 | Morgan Stanley Expansion Capital and Ally Bridge Group Lead $135 Million Investment in Elligo | Proceeds Used to Acquire ClinEdge and Invest Further in Technology & Data Platform
With access to over 150 million diverse patients, Elligo combines proprietary data, technology, and services to support all trial designs — traditional,... |
| 19.08.2021 | Ally Bridge Portfolio News – Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test | GRAIL will remain a separate and independent unit, pending ongoing regulatory and legal review
SAN DIEGO, Aug. 18, 2021 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) announced today that it has acquired GRAIL, a healthcare company focused o... |
| 04.08.2021 | Ally Bridge Portfolio News – Sonoma Biotherapeutics Raises $265 Million in an Oversubscribed Series B Financing to Translate the Promise of Cell Therapy into Curative Medicines for Autoimmune and Othe... | Sonoma Biotherapeutics’ platform and product candidates aim to restore immune system balance through complementary regulatory T cell (Treg) therapy and effector T cell (Teff) conditioning
Series B financing comprised of strong syndicate of... |
| 16.07.2021 | Ally Bridge Portfolio News – Rapid Micro Biosystems Announces Pricing of Initial Public Offering | July 14, 2021 21:30 ET | Source: Rapid Micro Biosystems, Inc.
LOWELL, Mass., July 14, 2021 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“Rapid Micro”), an innovative life sciences technology company providing mission cri... |
| 16.07.2021 | Ally Bridge Portfolio News – Imperative Care Raises $260 Million to Advance Innovations that Elevate Stroke Care
Contacts | Imperative Care to Create Strategic Network of Wholly Owned Development Subsidiaries in Areas of Synergy, Starting with Acquisition of Truvic Medical, Inc., a Peripheral Thrombectomy Innovator
Proceeds from the financing will be used to su... |
| 28.06.2021 | CMR Surgical raises $600 million in Series D financing, led by SoftBank Vision Fund 2 and co-led by Ally Bridge Group | June 28, 2021 07:00 ET | Source: CMR Surgical
CAMBRIDGE, UK – 28 June 2021, 07:01 (BST). CMR Surgical (CMR or “the Company”), a global surgical robotics business, today announces that it has raised $600 million (£425 million) in a Series D... |
| 05.06.2021 | Ally Bridge Portfolio News – GRAIL Presents Interventional PATHFINDER Study Data at 2021 ASCO Annual Meeting and Introduces Galleri, a Groundbreaking Multi-Cancer Early Detection Blood Test | — Galleri’s ability to detect more than 50 types of cancer with a single blood draw could transform early cancer detection as a complement to existing screenings; test now available in U.S. by prescription only —
MENLO PARK, Calif., June 4... |
| 06.05.2021 | Ally Bridge Portfolio News – Vida Health raises $110M in Series D round led by General Atlantic, Centene, and AXA Venture Partners | New capital to help Vida continue to scale virtual chronic mental and physical healthcare services after tripling revenue in 2020
Led by General Atlantic, the $110M Series D fundraise will help Vida continue to expand its network of provid... |
| 28.04.2021 | Ally Bridge Portfolio News – Ultivue Announces $50M Financing Round | April 27, 2021 10:07 AM Eastern Daylight Time
CAMBRIDGE, Mass.–(BUSINESS WIRE) –Ultivue, a leader in advancing precision medicine solutions through a unique approach that combines multiplex biomarker analysis with same slide traditional H&... |
| 16.03.2021 | Ally Bridge Portfolio News – Rapid Micro Biosystems Raises $81M to Continue Global Expansion of Automated Pharmaceutical QC Platform to Improve Data Integrity and Safety in Biologics, Vaccines, and Ce... | LOWELL, Mass., March 16, 2021 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc., the leading provider of data integrity and automation technology for microbial detection in biopharmaceutical manufacturing, today announced the completion of an... |
| 03.03.2021 | RefleXion Adds Ally Bridge Group to Investor Syndicate | Expands Series D financing by $40M
March 02, 2021 10:00 AM Eastern Standard Time
HAYWARD, Calif.–(BUSINESS WIRE)–RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT)* for all stages of... |
| 17.02.2021 | ABG Acquisition Corp. I Announces Pricing of Upsized $131 Million Initial Public Offering | NEW YORK and HONG KONG, Feb. 16, 2021 /PRNewswire/ — ABG Acquisition Corp. I (the “Company”) today announced the pricing of its initial public offering of 13,100,000 Class A ordinary shares at a price of $10.00 per share. The shares will be... |
| 16.02.2021 | Ally Bridge Group Co-leads Mainstay Medical’s $108 Million Equity Financing
Contacts | Funding to support U.S. commercial launch and global expansion
DUBLIN–(BUSINESS WIRE)–Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced the closing of an equity financing in which it raised gross proceeds of US$10... |
| 08.02.2021 | Ally Bridge Portfolio News – Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Corp III | Nautilus Biotechnology has entered into a definitive merger agreement with Arya Sciences Acquisition Corp III (Nasdaq: ARYA). Upon closing, the combined company is expected to be listed on Nasdaq under the ticker symbol “NAUT”
Nautilus Bio... |
| 03.02.2021 | Syapse Announces $68 Million Strategic Investment with Ally Bridge Group and Northpond Ventures to Expand Delivery of Real-World Evidence Through Syapse’s Learning Health Network | February 02, 2021 10:00 ET
— Financing to support expanded partnering opportunities with life sciences, health systems, regulators and molecular labs —
— Syapse committed to delivering real-world insights to improve outcomes for people wi... |
| 18.12.2020 | Ally Bridge Portfolio News – Hua Medicine Successfully Completes Its Registration Phase III Trials. Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin’s Phase III Combination with Metformin Tr... | Hua Medicine (the”Company”, Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced:
Type 2 diabetes is a worldwide epidemic fueled by the inc... |
| 07.12.2020 | Ally Bridge Portfolio News – Syros Acquires Clinical-Stage Drug Candidate for Acute Promyelocytic Leukemia, Expanding Its Pipeline of Targeted Therapies for Hematologic Malignancies | Oral Arsenic Trioxide has Potential to Reduce Treatment Burden of Standard-of-Care Regimen that Cures Most Patients
Dose Confirmation Study Expected to Begin in Second Half of 2021, Followed by Registration-Enabling Phase 3 Trial in 2022
... |
| 19.11.2020 | MedAvail Completes $84 Million Private Placement Led by Ally Bridge Group | MISSISSAUGA, Ontario & PHOENIX–(BUSINESS WIRE)–MedAvail Holdings, Inc. (“MedAvail”), a leading technology-enabled pharmacy organization that embeds automated pharmacy services directly into clinics and other points of care through its p... |
| 18.11.2020 | Ally Bridge Portfolio News – MedAvail and MYOS RENS Technology Announce Closing of Business Combination | MedAvail, Inc. Set to Trade on NASDAQ Under Ticker Symbol “MDVL”
MISSISSAUGA, Ontario & CEDAR KNOLLS, N.J.–(BUSINESS WIRE)–MedAvail, Inc. (“MedAvail”), a leading technology-enabled pharmacy organization that embeds pharmacy services di... |
| 31.10.2020 | Ally Bridge Portfolio News – Atea Pharmaceuticals Announces Pricing of Initial Public Offering | BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of pa... |
| 28.10.2020 | Ally Bridge Portfolio News – Nuvation Bio and Panacea Announce Business Combination Agreement, Creating a Publicly Listed Leader in Oncology Drug Development | NEW YORK – – October 21, 2020 – Nuvation Bio, Inc., a biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of the greatest needs in oncology, and Panacea ... |
| 28.10.2020 | Ally Bridge Portfolio News – Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Develop and Distribute AT-527 for Patients with COVID-19 | Roche Obtains Exclusive Right to Develop and Distribute AT-527 Outside the United States
BOSTON, Mass., October 22, 2020 – Atea Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering, developing and commer... |
| 28.10.2020 | Ally Bridge Portfolio News – miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc. | Acquisition includes clinical stage anti-IGF–1R monoclonal antibody, VRDN-001, intended for the treatment of thyroid eye disease (TED). Company plans to use private placement financing proceeds of $91 million to advance multiple compounds t... |
| 02.10.2020 | Ally Bridge Portfolio News – Pulmonx shares soar 118% in trading debut | (MarketWatch) — Shares of Pulmonx, a maker of treatments for lung diseases including emphysema, rose 118% in their trading debut Thursday, after the company’s initial public offering priced above range. The deal priced at $19 a share, above... |
| 21.09.2020 | Ally Bridge Portfolio News – Illumina to Acquire GRAIL to Launch New Era of Cancer Detection | Accelerates Commercialization and Adoption of Transformative Multi-Cancer Screening Test with Potential to Detect More Cancers Earlier and Enable Better Outcomes
Adds Multi-Disciplinary Team and Capabilities Harnessing the Power of Next-Ge... |
| 21.08.2020 | Ally Bridge Portfolio News – Bayer and Hua Medicine announce commercialization agreement | August 17, 2020, Beijing and Shanghai, China
Beijing and Shanghai, China, August 17, 2020 – Bayer and Hua Medicine, a leading innovative drug development company, today announced a commercialization agreement and strategic partnership for ... |
| 21.08.2020 | Ally Bridge Portfolio News – Biotechs Tap Growing U.S. Government Support for Alzheimer’s Research | Federal funding for dementia and Alzheimer’s studies has surged, as venture funding focuses on other diseases
Aug 20, 2020 Wall Street Journal
Alzheon Inc. will be holding Phase 3 clinical trials of its oral drug ALZ-801 after receiving $... |
| 30.07.2020 | Ally Bridge Portfolio News – Cerevel Therapeutics and Arya Sciences Acquisition Corp II Announce Business Combination, Creating a Publicly Listed Leader in Neuroscience Drug Development | July 30, 2020 07:00 AM Eastern Daylight Time
BOSTON–(BUSINESS WIRE)–Cerevel Therapeutics, Inc. (“Cerevel Therapeutics”), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, and Arya Sciences Acquisi... |
| 07.07.2020 | Ally Bridge Portfolio News – Unum Therapeutics Inc. Announces Acquisition of Kiq LLC | CAMBRIDGE, Mass. and PHILADELPHIA, July 6, 2020 /PRNewswire/ — Unum Therapeutics Inc. (“Unum”) (NASDAQ: UMRX), a biopharmaceutical company focused on developing therapies for solid tumors, today announced it has completed the acquisition of... |
| 02.07.2020 | Ally Bridge Portfolio News – Goldfinch Bio Secures $100 Million in Series B Financing | Proceeds Support Advancement of Lead Product Candidates GFB-887 and GFB-024 Through Three Clinical Proof-of-Concept Readouts
Oversubscribed Round Includes Public Healthcare Funds
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Goldfinch Bio, a clinical ... |
| 20.06.2020 | Ally Bridge Portfolio News – Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin’s Phase III Monotherapy Trial | June 18, 2020, Shanghai, China
Hua Medicine (the “Company”, Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED ... |
| 09.06.2020 | Ally Bridge Portfolio News – World Premiere for Quantum Surgical’s Medical Robot at Montpellier University Hospital | Montpellier, France, June 8, 2020 – On June 4, 2020, Professor Boris GUIU and his team at Montpellier University Hospital (France) successfully treated a 56-year-old patient with liver tumor using Quantum Surgical’s medical robot. Quantum S... |
| 21.05.2020 | Ally Bridge Portfolio News – Rapid Micro Biosystems Raises $120 Million to Accelerate Global Expansion of Contaminant Testing Platform for Pharmaceutical and Vaccine Manufacturing | LOWELL, Mass.–(BUSINESS WIRE)–Rapid Micro Biosystems, Inc., the leading provider of fully automated, high-throughput, rapid microbial detection technology for biopharmaceutical manufacturing, today announced the completion of a $120 million... |
| 21.05.2020 | Ally Bridge Group Leads US$150 million Financing for Three U.S. Companies Amidst the COVID-19 Pandemic, Bringing Total Ally Bridge-led Private Life Science and Healthcare Investments to US$650 million... | “The COVID-19 pandemic is undoubtedly a watershed event for life science and healthcare around the globe, and further strengthens ABG’s commitment to leading high-impact investments in game-changing innovations in this space,” said Frank Yu... |
| 21.05.2020 | Ally Bridge Portfolio News – Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing |
BOSTON, May 20, 2020 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections, today announced a $215 million Ser... |
| 09.05.2020 | Ally Bridge Portfolio News – GRAIL Announces $390 Million Series D Financing | MENLO PARK, Calif. — (BUSINESS WIRE) — GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced a $390 million Series D financing round. New investors including Public Sector Pension I... |
| 06.05.2020 | Ally Bridge Group Leads Pulmonx’s $66mn Financing to Support Commercial Acceleration of the Zephyr Valve System | REDWOOD CITY, Calif.–(BUSINESS WIRE)–Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally-invasive treatment for patients with severe emphysema, announces a $66 million financing led by Ally Bridge Gr... |
| 01.05.2020 | Ally Bridge Group Leads Vida Health’s $25mn Financing to Scale Network and Meet Increased Demand for Virtual Care | San Francisco, April 30, 2020 — Virtual healthcare platform, Vida Health, announced today that it raised $25 million in new funding to meet the increased demand for mental and physical virtual care. The funding was led by Ally Bridge Group ... |
| 16.03.2020 | Ally Bridge Portfolio News – WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19 | SAN FRANCISCO and SHANGHAI, Feb. 25, 2020 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufa... |
| 21.02.2020 | Ally Bridge Group leads $30 mln investment in Israel’s Mavrik Dental | JERUSALEM, Feb 18 (Reuters) – Israel’s Mavrik Dental Systems has raised $30 million in a funding round led by life sciences investment firm Ally Bridge Group (ABG), the companies said on Tuesday.
Mavrik provides technologies for in-office ... |
| 19.02.2020 | Ally Bridge Group Leads US$70 million Investments in Two Israeli Life Science Companies over the Last 2 Months | TEL AVIV, Israel, HONG KONG and NEW YORK, Feb. 18, 2020 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading global life science investment group, has announced that it recently led US$70 million investments in two Israeli life sciencecompan... |
| 16.12.2019 | Ally Bridge Group Leads More Than US$140 million in Financings for Three New Medtech Investments, Bringing Total Ally Bridge-led Private Life Science Investments to Above US$500 million over the Last ... | HONG KONG and NEW YORK, Dec. 16, 2019 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading global life science investment group, has announced that it recently led investments in three new medical technology companies. Each of the three comp... |
| 11.12.2019 | Ally Bridge Group Co-leads Imperative Care’s $85 Million Series C Financing | CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced that it has completed the initial closing of a Series C financing of $85 million to support the commercial launch of the company’s portfolio, which is composed of the la... |
| 04.12.2019 | Ally Bridge Group Leads Venclose’s $27 Million Series C Funding | SAN JOSE, Calif., Dec. 3, 2019 /PRNewswire/ — Venclose, Inc., a privately-held Silicon Valley medical device company focused on innovative treatment procedures for venous reflux disease, today announced it has closed its Series C funding le... |
| 10.05.2019 | Ally Bridge Portfolio News – Pulmonx Closes $65 Million Financing and Adds Chief Financial Officer | REDWOOD CITY, Calif.–(BUSINESS WIRE)–Pulmonx Corporation, a global leader in diagnostic and therapeutic pulmonary device technologies, announced today the closing of an oversubscribed $65 million equity financing and the hiring of Derrick S... |
| 10.05.2019 | Ally Bridge Group Leads Pulmonx’s $65 Million Financing, Further Strengthening Its Global Medtech Franchise | HONG KONG, May 9, 2019 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading global life science investment group, announced today that it led an over-subscribed $65 million financing of Pulmonx Corporation, a global leader in diagnostic and ... |
| 04.04.2019 | Ally Bridge, LifeTech Scientific and Quantum Surgical Announce Three-Way China Joint Venture to Develop Innovative Surgical Robot for the Treatment of Liver Cancer | HONG KONG, SHENZHEN, China, and Montpellier, France, April 4, 2019 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading cross-border life science investment group, announced today that it has entered into an agreement with LifeTech Scientifi... |
| 08.03.2019 | Ally Bridge Portfolio News – ShockWave Medical shares soared by more than 79% in its Wall Street debut | ShockWave Medical Inc. shares soared by more than 79 percent in its Wall Street debut on Thursday after it raised nearly $97 million in an upsized IPO.
The Santa Clara life sciences company sold 5.7 million shares of common stock for $17 a... |
| 08.03.2019 | Ally Bridge Portfolio News – ShockWave Medical prices upsized IPO above the range at $17 | SANTA CLARA, Calif., March 06, 2019 (GLOBE NEWSWIRE) — ShockWave Medical, Inc. (“ShockWave”) today announced the pricing of its initial public offering of 5,700,000 shares of its common stock at a price to the public of $17.00 per share. Th... |
| 13.12.2018 | Ally Bridge Portfolio News – Wuxi Apptec Successfully Prices Hong Kong Offering in Stormy market | BioCentury – Dec 8, 2018
Despite global trade headwinds and a choppy market for biopharma stocks in China, WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) successfully price its Hong Kong listing within its proposed range Friday, raising... |
| 13.12.2018 | Ally Bridge Portfolio News – WuXi AppTec Completes Secondary Listing in HKEx After Fast-Track A-Share IPO | HONG KONG and SHANGHAI, December 12, 2018– WuXi AppTec Co., Ltd. (Stock code: 603259.SH/2359.HK) today announced the successful secondary listing on the Main Board of the Hong Kong Stock Exchange, just seven months after it went public in S... |
| 06.12.2018 | Ally Bridge Portfolio News – TESARO reaches agreement to be acquired by GSK | LONDON and WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) — GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TES... |
| 15.11.2018 | Ally Bridge Portfolio News – Vapotherm Shares Soar 14.29% in Trading Debut | Vapotherm Inc, which provides noninvasive breathing aids to treat respiratory distress, raised $56 million by offering 4 million shares at $14. The stock started trading on the New York Stock Exchange Wednesday, under the ticker symbol “VAP... |
| 01.11.2018 | Ally Bridge Portfolio News – Axonics IPO Opened Strong at $16.05/Share (+7%), against a fragile market | October 30, 2018 Business Wire
RVINE, Calif.–(BUSINESS WIRE)–Axonics Modulation Technologies, Inc. (“Axonics”), a medical technology company focused on the design, development and commercialization of innovative and minimally invasive sacr... |
| 01.11.2018 | Ally Bridge Portfolio News – Innovent Biologics hikes on HK debut amid cloudy market sentiments | October 31, 2018 ENDPOINTS NEWS
Innovent Biologics has surged on its closely watched Hong Kong IPO, hitting a 21% rise at one point and ending the day at 18.6% above its IPO price after raising a record setting $421 million. The Suzhou-bas... |
| 19.09.2018 | BioCentury – HUA’S INSTITUTIONAL ADVANTAGE | HUA’S INSTITUTIONAL ADVANTAGE
HOW DIABETES COMPANY HUA NAVIGATED VOLATILE HONG KONG MARKET TO PRICE IPO
8:17 AM CST | SEP 15, 2018 | BIOCENTURY
The same market forces that drove Hua Medicine Ltd. to reduce the size of its Hong Kong IPO t... |
| 19.09.2018 | Ally Bridge Portfolio News – Hua Medicine Raises $110mn in Hong Kong IPO | SEP 14, 2018 | BioCentury
Diabetes company Hua Medicine Ltd. (HKSE:2552) raised HK$867 million ($110.5 million) in an IPO through the sale of 104.8 million shares at HK$8.28. EVP and CFO George Lin said the offering, which priced at the lo... |
| 19.09.2018 | BioCentury – WUXI APPTEC QUEUES UP FOR HONG KONG LISTING | Less than five months after its IPO in Shanghai, WuXi AppTec Co. Ltd. (Shanghai:603259) proposed Tuesday to list on the Hong Kong stock exchange in an offering underwritten by Morgan Stanley Asia, Huatai Financial Holdings (Hong Kong) and G... |
| 19.09.2018 | Ally Bridge Portfolio News – WuXi AppTec Said to File for $1 Billion-Plus Hong Kong Offering | September 18, 2018, Bloomberg Report
WuXi AppTec Co., the Chinese contract medical researcher, has submitted an application for a Hong Kong share sale, according to people with knowledge of the matter.
The offering could raise more than $... |
| 31.07.2018 | Ally Bridge Portfolio News – ABG Among Cornerstone Investors in US$933mn BeiGene Secondary Hong Kong Listing |
Bloomberg / July 27, 2018, 10:48 PM GMT+8
BeiGene Ltd., a cancer drug developer, is seeking as much as HK$7.32 billion ($933 million) through a secondary listing in Hong Kong after debuting in New York in 2016.
The biotech firm is offer... |
| 31.07.2018 | Ally Bridge Portfolio News – Innovent Announced $150 Million Series E | ChinaBio Today Report / Apr 29, 2018
Innovent of Suzhou announced its series E financing of $150 million. Capital Group Private Markets (CGPM) is leading this investment with $90 million, followed by other investors including Cormorant Ass... |
| 31.07.2018 | Ally Bridge Portfolio News – I-Mab Successfully Raised USD 220 Million in Series C Funding | SHANGHAI, June 29, 2018 /PRNewswire/ — I-Mab Biopharma, a company focusing on innovative Biologics in therapeutic areas of immuno-oncology and immuno-inflammation, announced the completion of Series C financing for USD 220 million, represen... |
| 31.07.2018 | Ally Bridge Portfolio News – Chinese sovereign wealth fund backs LinkDoc’s $151m Series D | Deal Street Asia / Jul 5, 2018
China Investment Corporation (CIC), a sovereign wealth fund has participated in a RMB1 billion (US$151 million) series D round in Beijing-based oncology, big data firm LinkDoc Technology Ltd.
Following in th... |
| 31.07.2018 | BioCentury – Ally Bridge invests in Tasly Biopharmaceuticals |
Tasly Biopharmaceuticals Co. Ltd. (Shanghai, China) said Wednesday it issued 75.7 million new shares, representing about 7% of the company, as it prepares for a possible IPO.
The investors, which include Ally Bridge LB Healthcare Fund, P... |
| 31.07.2018 | Ally Bridge Group News: BioCentury Report – CHINA COMES TO EUROPE |
The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of investors looking for high quality ... |
| 12.07.2018 | Ally Bridge Group News: Endpoint News – 12 top China VCs you need to know who are making a transpacific splash |
Money is rushing into biotech at breakneck speed this year, and one part of the globe is accounting for much of the uptick: China. VC deals were teeming with Chinese investors in the first half of the year, with China-based firms particip... |
| 04.06.2018 | Ally Bridge Portfolio News – Ally Bridge Group Expands Early-stage Cancer Solution Portfolio with Investment in Quantum Surgical | HONG KONG and MONTPELLIER, France, June 3, 2018 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading cross-border life science investment group, has completed a Series A investment, as the first part of a total of $50 million raise, in Quant... |
| 23.05.2018 | Ally Bridge Portfolio News – Ally Bridge Group Leads GRAIL’s $300 Million Series C Financing | HONG KONG, May 21, 2018 /PRNewswire/ — Ally Bridge Group, a global life science-focused investment group, today announced that it has led a $300 million financing completed for GRAIL, Inc., a healthcare company whose mission is to detect ca... |
| 23.05.2018 | Ally Bridge Portfolio News – GRAIL Announces $300 Million Raised in Oversubscribed Series C Financing | MENLO PARK, Calif. & HONG KONG–(BUSINESS WIRE) — GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced it has raised USD$300 million in an oversubscribed Series C financing. The... |
| 08.05.2018 | Ally Bridge Portfolio News – WUXI APPTEC PRICES A-Share IPO | Hong Kong and Shanghai, May 8, 2018 / BioCentury / – – Services and manufacturing company WuXi AppTec Co. Ltd. (Shanghai:603259) raised RMB2.3 billion ($354 million) through the sale of 104.2 million shares at RMB21.60 in an IPO underwritte... |
| 27.03.2018 | Ally Bridge Portfolio News – Hua Medicine Raises $117.4 Million in Series D & Series E Financing | Hua Medicine, a clinical-stage drug development company developing novel therapies for the treatment of Type 2 diabetes, announced the closing of a combined Series D & Series E financing of US$ 117.4 million. The financing included new ... |
| 21.03.2018 | Ally Bridge Portfolio News – Boston Scientific Announces Agreement To Acquire NxThera | Acquisition expands portfolio with minimally invasive treatment option for patients with benign prostatic hyperplasia
MARLBOROUGH, Mass., March 21, 2018 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced that it has entered into ... |
| 08.01.2018 | Ally Bridge Group and LifeTech Scientific Form China-Global Medtech Investment and Operating Partnership | Hong Kong, Shenzhen and San Francisco, January 7, 2018 – Ally Bridge Group (“ABG”), a global healthcare-focused investment firm, has entered into a strategic partnership with LifeTech Scientific Corporation (SEHK: 1302), a leading innovativ... |
| 28.08.2017 | Synlogic Completes Merger with Mirna Therapeutics | CAMBRIDGE, Mass. & AUSTIN, Texas–(BUSINESS WIRE)–Aug. 28, 2017– Synlogic, Inc. and Mirna Therapeutics, Inc. today announced that the proposed merger of the two companies has closed following the approval of Mirna’s stockholders received... |
| 15.06.2017 | PE-backed WuXi Biologics completes Hong Kong re-listing | WuXi Biologics, a Chinese contract R&D services provider to the global pharmaceutical industry that was taken private by a PE-backed consortium in late 2015, gained 38% on its Hong Kong trading debut following a HK$3.97 billion ($510 mi... |
| 25.05.2017 | Ally Bridge reaches ‘inflection point’ with Wuxi IPOs – Profiler | Ally Bridge, the healthcare investment group that whisked Shanghai-based Wuxi Pharmatech from under the noses of established global private equity firms in 2015, is “reaching an inflection point”, according to founder Frank Yu.
Established... |
| 24.05.2017 | Wuxi Biologics, Wuxi Apptech’s IPOs could benefit from scarcity value – Ally Bridge founder Frank Yu | The listings of Wuxi Biologics in Hong Kong and the remainder of WuxiPharmatech‘s assets in China will benefit from their scarcity value, according to Frank Yu, founder of Ally Bridge, the firm that led the delisting the Shanghai-based Wuxi... |
| 16.03.2017 | Aerpio Pharmaceuticals Raises $40 Million | Aerpio Pharmaceuticals, Inc. (the “Company”), a biopharmaceuticalcompany focused on advancing first-in-class treatments for ocular diseases, today announced thesuccessful completion of its reverse merger transaction with Aerpio Therapeutics... |
| 21.02.2017 | Ally Bridge Group Expands European Life Science Portfolio with New Investments and Establishes Presence in Europe | HONG KONG and ZUG, Switzerland, Feb. 21, 2017 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading global cross-border healthcare investment group, announced that in recent months it has completed investments in two European biopharmaceutica... |
| 15.08.2016 | Serving returns: How Ally Bridge expects to build on top of WuXi arbitrage play | China’s Ally Bridge Group hit the investment world’s radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that move with the listing of WuXi’s biologic... |
| 18.07.2016 | Ally Bridge Group Congratulates Medtech SA on its Acquisition by Zimmer Biomet | HONG KONG, July 18, 2016 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading China-global cross-border healthcare-focused investment group, is pleased to announce the sale of its entire stake in Medtech SA (“Medtech” or the “Company”) to Zi... |
| 03.05.2016 | Building a Global ‘Bridge’ for Life Science Innovation | By Hui Cai, VP of Corporate Alliances at WuXi AppTec (@HuiCai2)
As the globalization of healthcare expands, Frank Yu and his team at Ally Bridge Group continue to differentiate themselves in the market with strategic and fruitful investmen... |
| 19.04.2016 | Five Questions For Ally Bridge’s Founder Frank Yu | Frank Yu, founder of healthcare-focused investment firm Ally Bridge Group and formerly head of China Investments at Och-Ziff Capital Management, answers five questions in this video interview with Nina Xiang, host of China Money Podcast.
Q... |
| 04.04.2016 | Ally Bridge Group Expands Personalized Medicine Portfolio, Invests in LinkDoc Technology Limited, China’s Oncology Big Data Company | HONG KONG, April 4, 2016 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading cross-border healthcare-focused investment group, is pleased to announce the completion of its Series B investment into LinkDoc Technology Limited (“LinkDoc” or th... |
| 23.03.2016 | Ally Bridge keeps cash flowing in $155M private placement in Tesaro | Hong Kong-based Ally Bridge Group took a hand in a $155 million placement in immuno-oncology biotech Tesaro ($TSRO), joining a funding round led by Kleiner Perkins along with New Enterprise Associates in equal portions.
Under the terms, an... |
| 21.03.2016 | Ally Bridge Group (ABG) Completes Its Investment in TESARO, Inc. (TSRO) | HONG KONG, Mar. 21, 2016 /PRNewswire/ — Ally Bridge Group (“ABG”), a global healthcare-focused investment group, announced that it has completed an equity investment in TESARO, Inc. (NASDAQ: TSRO), an oncology-focused, commercial-stage biop... |
| 10.12.2015 | WuXi PharmaTech (Cayman) Inc. Announces Completion of Going Private Transaction | SHANGHAI, Dec. 10, 2015 /PRNewswire/ — WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operatio... |
| 14.08.2015 | Wuxi Pharmatech Enters Into Definitive Merger Agreement | SHANGHAI, Aug. 14, 2015 /PRNewswire/ — WuXi PharmaTech (Cayman) Inc. (“WuXi” or the “Company”) (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical devic... |
| 30.04.2015 | WuXi PharmaTech Announces Receipt of Proposal | SHANGHAI, April 30, 2015 /PRNewswire/ — WuXi PharmaTech (Cayman) Inc. (“WuXi” or the “Company“) (NYSE: WX), a leading global contract R&D services provider, today announced that its board of directors has received a preliminary non-bind... |
